Voluntary nationwide recall: Sodium Bicarb and Atropine (Hospira – December)
Jan. 2024Pharmacy Updates
Hospira Inc. is recalling several lots of 4.2% Sodium Bicarbonate Injection, USP, 8.4% Sodium Bicarbonate Injection, USP, and Atropine Sulfate Injection, USP. Sodium Bicarbonate is used for the treatment of metabolic acidosis (a buildup of acid in the body). Atropine Sulfate is used for temporary blockade of severe or life-threatening muscarinic effects (effects on certain nerves of the body).
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Sedgwick Inc. at 1-800-805-3093. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices
Important announcement – Telehealth submissions
As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.Sep. 2025Important Notices